Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M82,275Revenue (TTM) $M18,471Net Margin (%)18.2Altman Z-Score5.6
Enterprise Value $M83,064EPS (TTM) $2.0Operating Margin %19.2Piotroski F-Score5
P/E(ttm)24.4Beneish M-Score-2.0Pre-tax Margin (%)23.9Higher ROA y-yY
Price/Book5.210-y EBITDA Growth Rate %-3.5Quick Ratio1.3Cash flow > EarningsN
Price/Sales4.45-y EBITDA Growth Rate %-18.4Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow90.9y-y EBITDA Growth Rate %62.7ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %3.1PEG--ROE % (ttm)22.7Less Shares Outstanding y-yN
Payout Ratio %76.0Shares Outstanding M1,671ROIC % (ttm)15.8Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYT Rowe Price Equity Income Fund 2016-12-31 Add0.01%$49.23 - $59.61
($54.67)
$ 49.98-9%Add 0.81%3,125,000
BMYKen Fisher 2016-12-31 Add$49.23 - $59.61
($54.67)
$ 49.98-9%Add 0.52%653,730
BMYJulian Robertson 2016-09-30 Buy 5.11%$53.87 - $76.77
($64.24)
$ 49.98-22%New holding400,800
BMYVanguard Health Care Fund 2016-09-30 Add0.41%$53.87 - $76.77
($64.24)
$ 49.98-22%Add 7.84%48,804,797
BMYT Rowe Price Equity Income Fund 2016-09-30 Reduce-0.08%$53.87 - $76.77
($64.24)
$ 49.98-22%Reduce -6.77%3,100,000
BMYJoel Greenblatt 2016-09-30 Buy 0.06%$53.87 - $76.77
($64.24)
$ 49.98-22%New holding87,321
BMYRonald Muhlenkamp 2016-09-30 Reduce-0.03%$53.87 - $76.77
($64.24)
$ 49.98-22%Reduce -0.56%180,316
BMYMario Gabelli 2016-09-30 Reduce-0.03%$53.87 - $76.77
($64.24)
$ 49.98-22%Reduce -10.12%556,927
BMYRon Baron 2016-09-30 Reduce-0.02%$53.87 - $76.77
($64.24)
$ 49.98-22%Reduce -58.69%47,479
BMYKeeley Asset Management Corp 2016-09-30 Sold Out -0.01%$53.87 - $76.77
($64.24)
$ 49.98-22%Sold Out0
BMYKen Fisher 2016-09-30 Add$53.87 - $76.77
($64.24)
$ 49.98-22%Add 0.34%650,332
BMYDodge & Cox 2016-09-30 Reduce$53.87 - $76.77
($64.24)
$ 49.98-22%Reduce -0.28%71,958
BMYRonald Muhlenkamp 2016-06-30 Reduce-0.8%$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -14.54%181,340
BMYVanguard Health Care Fund 2016-06-30 Reduce-0.35%$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -5.23%45,257,309
BMYT Rowe Price Equity Income Fund 2016-06-30 Reduce-0.21%$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -17.52%3,325,000
BMYKeeley Asset Management Corp 2016-06-30 Buy 0.01%$63.88 - $74.29
($70.56)
$ 49.98-29%New holding2,960
BMYMario Gabelli 2016-06-30 Reduce-0.01%$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -5.26%619,627
BMYRon Baron 2016-06-30 Add$63.88 - $74.29
($70.56)
$ 49.98-29%Add 1.85%114,941
BMYFirst Eagle Investment 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -10.92%11,529
BMYDodge & Cox 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 49.98-29%Reduce -1.77%72,158
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTODirector 2016-09-08Sell21,600$56.87-13.28view
ANDREOTTI LAMBERTODirector 2016-08-25Sell23,200$59.17-16.65view
ANDREOTTI LAMBERTODirector 2016-07-08Sell23,200$74.45-33.75view
ANDREOTTI LAMBERTODirector 2016-06-28Sell23,200$72.14-31.63view
Elicker John ESVP, Public Affairs & IR 2016-06-14Sell11,820$72.69-32.15view
Bancroft Charles AEVP & CFO 2016-05-20Sell30,201$70.79-30.33view
Caldarella Joseph CSVP & Controller 2016-05-16Sell3,519$72.47-31.94view
LEUNG SANDRAEVP, General Counsel 2016-05-06Sell72,544$70.39-29.93view
ANDREOTTI LAMBERTODirector 2016-05-05Sell23,200$70.54-30.08view
Caforio GiovanniCEO 2016-05-03Sell34,594$71.31-30.84view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Biotech Stocks to Watch After Senate Drug Report Dec 27 2016 
Looking for Moat Stocks Dec 20 2016 
Signature Select Canadian Fund 3rd Quarter Commentary Dec 14 2016 
Early Hedge Funder Julian Robertson Buys 2 Positions in 3rd Quarter Nov 14 2016 
52-Week Company Lows Nov 03 2016 
Baron Funds Comments on Bristol-Myers Squibb Co. Oct 25 2016 
52-Week Company Lows Oct 21 2016 
The Time Is Right to Pick Up Bristol-Myers Squibb Oct 17 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
52-Week Company Lows Oct 07 2016 

More From Other Websites
Bristol-Myers, Target Sink into Friday’s 52-Week Low Club Jan 20 2017
Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with... Jan 20 2017
Bristol-Myers Dives To 2-Year Low On Opdivo Lung Cancer Setback; Merck Jumps Jan 20 2017
Bristol's Opdivo Dependence Now Looks Dicey Jan 20 2017
Bristol-Myers shares fall on lung cancer timeline setback Jan 20 2017
Bristol-Myers shares fall on lung cancer timeline setback Jan 20 2017
Bristol-Myers Squibb: There Goes Any Chance for Upside Jan 20 2017
Bristol-Myers shares fall on lung cancer timeline setback Jan 20 2017
Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know Jan 20 2017
Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open... Jan 20 2017
Stocks Up Nicely In Early Trade; Apple Shrugs Off China Trade Talk Jan 20 2017
[$$] Bristol-Myers shares slide on immunotherapy setback Jan 20 2017
9:35 am Bristol-Myers gaps down nearly -10% to bring its Oct/Nov lows in play around the 49/50 area Jan 20 2017
Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy Jan 20 2017
Setback for Bristol-Myers on Lung Cancer Treatment Drugs Jan 20 2017
Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly Jan 20 2017
Bristol-Myers Squibb stock sinks 7.2% after it says it won't pursue accelerated approval for lung... Jan 20 2017
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race Jan 19 2017
Bristol-Myers won't seek accelerated Opdivo lung cancer approval Jan 19 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)